Michael P Blair to Bevacizumab
This is a "connection" page, showing publications Michael P Blair has written about Bevacizumab.
Connection Strength
4.885
-
Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019 06 01; 50(6):337-343.
Score: 0.633
-
Foveal Development After Use of Bevacizumab for Aggressive Posterior Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2019 06 01; 50(6):e185-e187.
Score: 0.633
-
Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2018 11 01; 49(11):893-896.
Score: 0.608
-
Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844). Ophthalmology. 2017 10; 124(10):e74-e75.
Score: 0.564
-
Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017 03 01; 48(3):255-259.
Score: 0.541
-
Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2016 Mar; 47(3):280-3.
Score: 0.505
-
Macular Sequelae Following Exudative Retinal Detachment After Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2020 Dec 01; 51(12):698-705.
Score: 0.176
-
Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity. J AAPOS. 2020 06; 24(3):149.e1-149.e5.
Score: 0.169
-
Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. J AAPOS. 2019 04; 23(2):88.e1-88.e6.
Score: 0.155
-
Reply. Retina. 2019 01; 39(1):e2-e4.
Score: 0.154
-
Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226). Ophthalmology. 2018 10; 125(10):e70-e71.
Score: 0.151
-
PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY. Retina. 2018 Apr; 38(4):764-772.
Score: 0.146
-
CONCURRENT SCLERAL BUCKLE AND INTRAVITREAL BEVACIZUMAB FOR ADVANCED RETINOPATHY OF PREMATURITY-RELATED RETINAL DETACHMENT. Retin Cases Brief Rep. 2016; 10(2):183-6.
Score: 0.125
-
Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol. 2010 Aug; 128(8):1080-1.
Score: 0.086
-
Smartphone application links severity of retinopathy of prematurity to early motor behavior in a cohort of high-risk preterm infants. J AAPOS. 2023 02; 27(1):12.e1-12.e7.
Score: 0.051
-
Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2021 09; 41(9):2377-2378.
Score: 0.046
-
Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis. Retin Cases Brief Rep. 2014; 8(1):24-9.
Score: 0.027
-
Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013 Jun; 17(3):323-5.
Score: 0.026
-
Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012 Aug; 130(8):1000-6.
Score: 0.025
-
Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012 Jun; 130(6):801-2.
Score: 0.024
-
Acquired vasoproliferative retinal tumor: a late sequela of retinopathy of prematurity. Arch Ophthalmol. 2011 Sep; 129(9):1234-5.
Score: 0.023
-
Intravitreal bevacizumab for neovascular glaucoma. J Ocul Pharmacol Ther. 2009 Oct; 25(5):453-8.
Score: 0.020